We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Data from a 4-year study conducted in one French facility suggest that PCR is a beneficial “add-on” to routine culture to diagnose patients with a suspected bone and joint infection.
Between November 2007 and October 2011, researchers conducted a prospective study at Lariboisière University Hospital in Paris that included patients with suspected infectious spondylodiscitis, septic arthritis and prosthetic joint infections, as well as respective noninfected groups.
They collected clinical and radiological data at the start of the study and during follow-up, and tested samples by conventional culture and using 16S rDNA PCR (16S-PCR). They also tested the samples of spondylodiscitis using cultures and PCR targeting Mycobacterium tuberculosis (MT-PCR). An expert committee confirmed or rejected suspicion of infections and classified patients into the case or control group.
The final analysis included 105 bone and joint infections (BJI) and 111 controls. According to the study, 30% of pathogens detected were staphylococci, 19% were M. tuberculosis and 14% were streptococci.
For diagnosing M. tuberculosis spondylodiscitis, culture alone demonstrated 42.2% sensitivity. With the addition of a PCR test to culture, sensitivity increased to 64.4% (P < .01). Similarly, for nonstaphylococci BJI diagnoses, culture alone demonstrated 71.3% sensitivity compared with 81.6% for culture with PCR (P < .01).
Moreover, 16S-PCR detected BJIs that were caused by uncommon bacteria, including Mycoplasma and fastidious bacteria, which the researchers noted as being interesting.
“In case of high suspicion of bone and joint infection, 16S-PCR must be considered, particularly when cultures remain negative, keeping in mind that performance depends on the pathogens involved,” the researchers wrote. “New technologies, such as microarrays and next generation sequencing, are promising approaches for the diagnosis of BJI and must be assessed with similar clinical definitions of infected patients and controlled trials.” – by Marley Ghizzone
Disclosures: The authors report no relevant financial disclosures.